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All cellular proteins are subject to quality control ‘‘decisions,’’ which help to prevent or delay
a myriad of diseases. Quality control within the secretory pathway creates a special challenge,
as aberrant polypeptides are recognized and returned to the cytoplasm for proteasomal degrada-
tion. This process is termed endoplasmic-reticulum (ER)-associated degradation (ERAD).The textbook view of the endoplasmic reticulum (ER) consists of
an undulating form situated between the nucleus and Golgi
stacks and freckled with dark circles that depict bound ribo-
somes. In the early years, those of us who obsessed over the
inner workings of the ER emphasized that roughly one-third of
newly synthesized proteins enter this organelle, an event that
serves as the first stop in the journey taken by secreted and
membrane proteins. Nevertheless, the ER was frequently
considered as a simple way station in an efficient assembly
line. Indeed, under most experimental conditions, the ER was
thought to dutifully fold and process nascent proteins before
they are encapsulated into Golgi-targeted vesicles. Only later
did we realize that we had been fooled: perturbations in protein
folding and ER homeostasis trigger a signaling cascade—the
unfolded protein response (UPR)—that profoundly impacts
cellular and organismal health. Another surprise was the sizeable
fraction of proteins that fail to pass through the ER folding
combine. These polypeptides, which may be misfolded or
incompletely processed, are ejected from the ER and returned
to the cytoplasm. During or soon after entering the cytoplasm,
the polypeptides are ubiquitinated and degraded by the 26S pro-
teasome. These events are collectively referred to as ER-associ-
ated degradation (ERAD), and to date, >60 human diseases have
been linked to the ERAD pathway (Guerriero and Brodsky, 2012).
Studies on ERAD have benefited from a range of experimental
strategies in yeast and mammalian cells, and recent reports
have shed light on the mechanisms underlying the ERAD
pathway. In this Minireview, the focus is on some of these
discoveries and the open questions that remain in this field.
Are You a Good Protein or a Bad Protein?
Polypeptides entering the secretory pathway are received at the
ER membrane by the Sec61 protein translocation channel in
a nonnative state (Braakman and Bulleid, 2011). Most of these
polypeptides are posttranslationally modified by the signal pepti-
dase, by the glycosylation machinery, and/or by lipid conjuga-
tion. The efficiencies of these events can be altered by the
UPR. In addition, each nascent protein transits between a signif-
icant and variable number of intermediate folding states. Protein
folding, which requires a cadre of ER-associated molecular
chaperones, is also compromised by stress as well as by pertur-bations in the ER’s specialized environment, which is more
oxidizing than the cytoplasm and is calcium rich. Furthermore,
metabolic signal transduction pathways and developmental
processes can induce the UPR. Combined with the fact that
genetic mutations are not that uncommon—and that errors in
transcription and translation arise—a significant number of
newly synthesized proteins in the ER never attain their native
states or do so quite slowly.
Can the cell risk the threat that these aberrant species pose?
Absolutely not, as unfolded proteins can aggregate or illegiti-
mately bind other proteins and exert dominant-negative effects.
Misfolded proteins exhibiting subtly altered conformations can
be secreted and form extracellular amyloids, as evidenced by
some cases of transthyretin amyloidosis (Sekijima et al., 2005).
However, ER chaperones and chaperone-like proteins more
commonly survey the conformations of nascent polypeptides
in the ER with high fidelity. Key members of these chaperone
classes areHsp70s (the Hsp70 in the ER lumen is BiP) and lectins
that bind to and in some cases modify the appended N-glycan
while facilitating polypeptide chain folding (Aebi et al., 2010).
The branched N-glycan moiety that is added onto most
secreted and membrane proteins is built from two N-acetylglu-
cosamines, nine mannoses, and three terminal glucose residues
at the end of one branch. Glucose trimming favors client protein
interactions with calnexin and calreticulin, which in turn facilitate
protein folding. If folding is attenuated, sequential rounds of re-
glucosylation and calnexin/calreticulin reassociation occur,
which sometimes leads to successful folding. The trimming of
mannose residues from one of the three branches competes
with folding and triggers ERAD, which prevents a futile and
unproductive folding cycle. Critical mediators of mannose trim-
ming and ERAD substrate selection are an ER mannosidase and
the ER-degradation-enhancing a-mannosidase-like protein-1
(EDEM1). Although this sequence of events is well supported,
recent reports have offered new views of how some of these
components function. For example, EDEM1 is not only a lectin,
but it can also directly recognize nonnative proteins, thereby ex-
hibiting chaperone activity. In fact, most ER lectins exhibit
peptide-binding activity. Instead of trimming mannose residues
on ERAD substrates, EDEM1’s mannosidase domain may
instead be utilized to interact with SEL1, an adaptor that linksCell 151, December 7, 2012 ª2012 Elsevier Inc. 1163
substrates to other components of the ERAD machinery (Corm-
ier et al., 2009). Moreover, EDEM1 overexpression—as occurs
during UPR induction—accelerates the degradation of both gly-
cosylated and unglycosylated proteins, overriding the need for
mannose trimming (Ron et al., 2011). Thus, the UPR short-
circuits a critical event that is otherwise imperative during glyco-
protein quality control. Further, based on the examination of
a relatively small number of substrates, it remains unknown
whether all glycosylated proteins are subjected to the calnexin
cycle. Finally, unglycosylated proteins that bind to BiP and func-
tion outside of the lectin folding cycle employ another factor,
Herp, to aid in targeting ERAD substrates to the proteasome
(Okuda-Shimizu and Hendershot, 2007). Our understanding of
themechanisms underlying the selection of glycosylated and un-
glycosylated ERAD substrates will certainly continue to evolve.
In contrast to the selection of soluble proteins within the ER,
the recognition of misfolded cytoplasmic domains in membrane
proteins appears at first glance to be simpler. By definition, these
proteins can access cytoplasmic chaperones that play well-
defined roles in protein folding and quality control. Hsp70 chap-
erones may bridge or help recruit distinct E3 ubiquitin ligases to
membrane proteins that fail to fold, and some ligases can oper-
ate sequentially (Nakatsukasa et al., 2008; Younger et al., 2006).
Why there are somany cytoplasmic chaperones is less clear (the
yeast and human cytoplasm play host to 7 and 8 Hsp70s,
respectively, plus an enlarged number of Hsp70 cochaperones),
and the rules governing substrate specificity between chaperone
classes and among members of even the same class are
undefined.
Shoot First, Ask Questions Later
In some instances, proteins are destroyed that might—under the
right circumstances—fold into their native structures. A promi-
nent example is the cystic fibrosis transmembrane conductance
regulator (CFTR), the protein that is linked to the most common
lethal inherited disease in Caucasians (Lukacs and Verkman,
2012). A significant fraction of the wild-type protein is targeted
for ERAD as a consequence of CFTR’s complex and inefficient
folding pathway and because it may take 30 min for the protein
to be translated and attain its native conformation. It is not
surprising then that the deletion of a single amino acid, F508,
pushes CFTR over the edge so that nearly the entire protein
pool is destroyed, which results in cystic fibrosis.
The CFTR folding pathway has been the focus of intense
research efforts. Recent data indicate the existence of two
thermodynamic peaks in the folding pathway that must be sur-
mounted: the first is the folding of a nucleotide-binding domain,
and the second is the association between this domain and the
fourth intracellular loop (Mendoza et al., 2012; Rabeh et al.,
2012). Consequently, the cure for cystic fibrosis might require
two drugs that each target one step. Based on this knowledge
and the development of technologies that monitor CFTR folding
and function, screens for DF508-CFTR correctors have been
performed. One effort led to the isolation of a potent and effica-
cious compound that restored the function of the most frequent
disease-causing mutant in cultured cells (Van Goor et al., 2011).
The compound is now in advanced clinical trials (http://www.
clinicaltrials.gov). Other compounds have shown efficacy in1164 Cell 151, December 7, 2012 ª2012 Elsevier Inc.cellular models of different diseases associated with the ERAD
pathway (Guerriero and Brodsky, 2012), but in most cases, it is
unknown how they function, and clinical trials are few and far
between.
Because DF508-CFTR can fold and then function at the
plasma membrane, cystic fibrosis may represent an example
for which ERAD is overzealous. In contrast, liver disease asso-
ciated with antitrypsin deficiency appears to arise from aggre-
gation or polymerization of the antitrypsin Z allele (ATZ), which
in its soluble form is an ERAD substrate. Here, an increase in
ERAD would lead to disease amelioration. Unfortunately,
specific small-molecule activators of ERAD are not yet avail-
able. However, the administration of an autophagy activator
lessened the pathological consequences of ATZ in a murine
liver disease model (Hidvegi et al., 2010). These data are in
line with several studies indicating that the ERAD and auto-
phagy pathways cooperate and open up the possibility of using
autophagy modulators to treat select diseases associated with
ER dysfunction.
Is the Retrotranslocation Channel a Jack of All Trades?
Once selected for degradation, soluble ERAD substrates in the
lumen must somehow gain access to the cytoplasmic protea-
some. Integral membrane proteins that are ERAD substrates
present a unique challenge: how are embedded membrane-
spanning domains discharged from the lipid bilayer? One
scenario is that Sec61 functions bidirectionally, facilitating both
nascent protein translocation and ‘‘retrotranslocation.’’
Evidence in support of this model continues to emerge from
genetic tools and through the use of model substrates in yeast
(see, for example, Scha¨fer and Wolf, 2009). Alternatively,
members of a family of membrane proteins (Der1 in yeast and
Derlin-1, -2, or - 3 in mammals) that organize several ERAD-
requiring components were proposed to function as retrotrans-
location channels. Intriguingly, members of the Derlin family
are similar to rhomboid proteases, but a catalytic dyad required
for activity is absent (Greenblatt et al., 2011). These and other
data (Horn et al., 2009) suggest that the Derlins instead bind
unfolded ERAD substrates in the membrane as they pass into
the cytoplasm and/or regulate the activities of other integral
membrane components of the ERAD machinery.
Although evidence indicates that some ERAD substrates with
folded domains efficiently transit into the cytoplasm (Tirosh et al.,
2003), other ERAD substrates containing residual structure may
have to unfold to fit through the confines of the retrotranslocation
channel. This event would require the breaking of disulfide
bonds. A candidate for the necessary disulfide reductase in
mammals is ERdj5. ERdj5 possesses four thioredoxin motifs
and also binds EDEM1, as well as BiP. Based on ERdj5’s struc-
ture and a series of biochemical studies, it was proposed that
a substrate passes sequentially from calnexin to the EDEM1-
ERdj5 complex and then on to the retrotranslocation channel,
an event that may be chaperoned by BiP (Hagiwara et al.,
2011). Over time, it will be exciting to discover whether ERdj5
acts on a diverse ensemble of ERAD substrates. It is also curious
that yeast lack an ERdj5 homolog. How disulfide bonds in ERAD
substrates are broken in the yeast ER—or whether this is
needed—is an open question.
Figure 1. Models for the Recognition, Targeting, and Degradation of Soluble and Integral Membrane ERAD Substrates
(A) The ERAD of soluble, lumenal substrates in yeast requires the action of the Hrd1 complex, whose members are depicted in this figure. Recognition of
a substrate by this complex follows selection by BiP and/or by lectins with chaperone-like properties (e.g., calnexin/calreticulin). Yos9 is also an ER lectin that
binds to Hrd3 (SEL1 in higher eukaryotes), and lectins that act similarly in mammals include Os9 and XTP-3B. Hrd1 is most intimately linked to substrate ret-
rotranslocation and ubiquitinates and delivers substrates to the Cdc48 complex, which harbors hexameric Cdc48 (p97 in mammals) and single copies of Ufd1
and Npl4. Cdc48 couples ATP hydrolysis with subsequent delivery to the proteasome. Cdc48 may also help to unfold and disaggregate substrates prior to
degradation and appears to be tethered to the ER via Ubx2. Der1 (Derlin-1, -2, and -3 in mammals) and Usa1 (the mammalian homolog is Herp) function as Hrd1
regulatory factors. Note that Der1 is depicted as containing six transmembrane segments, but some data are consistent with four membrane-spanning domains.
(B) During the ERAD of an integral membrane protein that contains a misfolded cytoplasmic domain (depicted with a green loop), a substrate is recognized
by cytoplasmic chaperones and is then ubiquitinated by Doa10 in yeast. Doa10 contains 14 transmembrane segments and, like Hrd1, has also been proposed
to act as a retrotranslocation channel. The Cdc48 complex extracts and maintains the solubility of the ERAD substrate before or concomitant with proteasome-
mediated degradation. Not shown in this figure are E2 ubiquitin-conjugating enzymes, which are integral membrane proteins or are tethered to the membrane,
as well as proteasome adaptors that aid in the final targeting of substrates to the proteasome. Also not shown is the pathway that leads to the degradation of a
protein with a misfolded lesion residing in a membrane-spanning segment, a process that also requires Hrd1. The ubiquitin ligase activities of Hrd1 and Doa10
are mediated by the RING domain that resides in the cytoplasm. In both panels, the ERAD substrate is depicted in red. See text for additional details and
(Xie and Ng, 2010).Another black box in the field is the mechanism by which
soluble ERAD substrates initially enter the cytoplasm. As there
is no obvious pushing force generated from the ER, a series of
handoffs between ERAD mediators and a substrate must ulti-
mately favor substrate transit into and then through a retrotrans-
location channel. Once a polypeptide enters the cytoplasm and
once misfolded membrane proteins are selected for ERAD, they
are polyubiquitinated; therefore, the acquisition of a polyubiquitin
chain may provide the necessary Brownian ratchet to facilitate
retrotranslocation. Based on these considerations and other
data, the field has increasingly focused on the relationship
between ubiquitin ligases and unique steps in the ERAD
pathway.
In contrast with the large number of ubiquitin ligases that
exist in eukaryotic cells, relatively few of these enzymes are
associated with the ER (Claessen et al., 2012). In yeast, the
two ER ligases are Hrd1 and Doa10. For many years, it was
curious why Hrd1 and Doa10, whose catalytic domains reside
in the cytoplasm, also possess multiple membrane spanningdomains. An exciting discovery was that Hrd1’s membrane-
spanning segments, along with soluble domains, appear to
recognize misfolded integral membrane regions in ERAD
substrates (Sato et al., 2009). Moreover, this ER resident E3
might even function as the long-sought retrotranslocation
channel for soluble substrates, thus coupling protein export
with the acquisition of a polyubiquitin tag. Crosslinking experi-
ments examining the early stages of substrate retrotranslocation
are consistent with the view that Hrd1 ushers soluble lumenal
substrates to the cytoplasm; in addition, cycles of Hrd1 oligo-
merization and monomerization are coupled to substrate
binding, ubiquitination, and degradation and Hrd1 associates
with factors that play critical roles during each of these events
(Carvalho et al., 2010; Horn et al., 2009) (Figure 1A). If protein
translocation into the ER is slowed, Hrd1 can even steal
substrates that otherwise use Doa10 (Rubenstein et al., 2012),
further implicating Hrd1 as a central player during ERAD. Still,
the inability to identify a universal channel for soluble substrates
is baffling. Might there be multiple retrotranslocation channels,Cell 151, December 7, 2012 ª2012 Elsevier Inc. 1165
such that different substrates utilize different channels (e.g.,
Sec61 versus the Hrd1 complex)? In turn, do integral membrane
proteins need a channel, or might they access the proteasome
directly or via a lipid droplet intermediate (Hartman et al.,
2010)? Stay tuned.
The ERAD Engine: Extraction and Delivery to the
Proteasome
Most ERAD substrates require a AAA protein, Cdc48 (in yeast) or
p97 (in mammals), to be extracted from the ER. Divergent
models depict substrates threading through the aperture of the
AAA hexamer, concomitant with ATP hydrolysis, or view the
protein acting as a segregase that dissolves stable membrane-
associated entities. Cdc48/p97 also serves as a platform on
which a variety of ERAD facilitators sit, including ubiquitin-
binding proteins, factors that link Cdc48/p97 to the proteasome,
and enzymes that can extend or reduce the length of the polyu-
biquitin chain (Stolz et al., 2011).
Surprisingly, integral membrane proteins can be fully solubi-
lized by Cdc48 and reside in the cytoplasm prior to degradation
(Figure 1B); in yeast, maximal solubilization requires polyubiqui-
tin chain extension, which may reflect increased avidity between
Cdc48 and the substrate (Garza et al., 2009; Nakatsukasa et al.,
2008). In mammalian cells, membrane protein solubilization is
aided by components of a complex that also target tail anchor
protein insertion into the ER (Wang et al., 2011), an event that
similarly requires the transport of hydrophobic species in the
cytoplasm. It is likely that other components help to solubilize
integral membrane ERAD substrates. Efficient solubilization is
critical, as cytoplasmic aggregates are toxic and prominent in
several diseases.
Open Questions and Future Research Directions
As uniformly evident in other research fields, studies on the
ERAD pathway have yielded more questions than answers.
Several of these questions fall into the following categories.
First, proteins that facilitate ERAD have been isolated through
genetic and biochemical attacks. The continued employment of
these approaches—in different cell types, under conditions in
which the delivery of a substrate is blocked so that intermediates
accumulate, and in animals—is vital. Undiscovered contributing
factors and substrate-specific ERAD modifiers most certainly
exist, and to date, next to nothing is known about the function
and regulation of the ERAD machinery in animals.
Second, ERAD is often viewed as a constitutive process or at
least one whose efficiency is modulated by the UPR (Jonikas
et al., 2009). Intriguingly, ERAD efficiency may be ‘‘tuned’’ via
the packaging of EDEM1 and Os-9 (another lectin that contrib-
utes to substrate selection) into vesicles targeted for lysosomal
degradation (Bernasconi et al., 2012). Surprisingly, this regula-
tory circuit occurs independently of UPR activation. These data
suggest that there may be other novel ways to modulate ERAD.
Third, a growing number of diseases are associated with the
ERAD pathway because a mutated protein is destroyed,
because a component of the ERAD machinery is defective, or
because the pathway is co-opted by pathogens. The ERAD
pathway is also used as a metabolic regulator, especially with
regard to events underlying lipid metabolism. In fact, the ERAD1166 Cell 151, December 7, 2012 ª2012 Elsevier Inc.of misfolded proteins might have evolved as a byproduct of
a more primal need to regulate the degradation of enzymes
and lipid carriers that reside in or pass through the ER. The pene-
trance and expressivity of ERAD-related diseases, especially
those involved in lipid metabolism, may be linked to genetic
polymorphisms. To date, few studies have correlated poly-
morphisms in ERAD substrates with disease presentation.
Undoubtedly, this pursuit will accelerate as genome sequencing
and personalized medicine become commonplace.
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